Older regional human studies report immune-marker effects and long-term gerontology/longevity signals, but the methods and independent replication do not support high contemporary certainty.
Regulatory status
No FDA/EMA-approved Thymalin medicine identified.
Main limitations
Reliable lifespan extension, modern replicated clinical efficacy, contemporary long-term safety or a validated anti-ageing regimen.
Safety
Modern standardized safety data and product equivalence are limited.
i
Older regional human studies report immune-marker effects and long-term gerontology/longevity signals, but the methods and independent replication do not support high contemporary certainty.
What the evidence actually supports
✓Publish as limited regional evidence, not proof that Thymalin extends human lifespan.
✓Adds human depth but does not strengthen broad anti-ageing/longevity claims.
✓Research coverage can be deep while certainty remains low.
What is not established / key limitations
×Independent modern randomized replication is lacking.
×Several other immune measures showed no substantial effect.
×Independent modern replication of the large longevity effect is lacking.
Selected study & evidence records
Peptides of pineal gland and thymus prolong human life
2003 · Long-term regional clinical report; randomization/blinding not clear from accessible abstract · n=266
The report describes lower morbidity and mortality in peptide-treated groups.
Thymalin added to standard treatment in non-specific pulmonary disease
1989 · Small controlled clinical study · n=35
Thymalin was associated with normalization of lymphocyte count and OKT-4+/OKT-8+ subpopulations; little effect was reported on several other immune measures.
Modern standardized safety data and product equivalence are limited.
Modern standardized safety data and product equivalence are limited.
Technical details
Mechanism / biologyHistorical thymic peptide preparation proposed to modulate immune/endocrine ageing pathways; composition/standardisation differs from single defined peptides.
Route / formulation boundaryHistorical preparations may not be compositionally equivalent to current commercial vials.
Identity / data-quality noteTreat large longevity claims as low-certainty due older regional methods and limited independent replication.
Dosing evidence statusVerified context-specific human IM study exposure added. A severe-COVID retrospective study used 10 mg intramuscularly once daily for 5 days alongside basic treatment. This is context-specific study exposure, not a general regimen, and product standardisation/equivalence remains uncertain.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
